|
Patent landscape, scope, and claims: |
United States Drug Patent 9,913,826: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 9,913,826, titled "METHODS FOR TREATING NEURODEGENERATIVE DISEASES." The patent claims methods of treating neurodegenerative diseases using specific pharmaceutical compositions. This analysis details the patent's scope, key claims, and positions it within the broader drug patent landscape, identifying potential competitive and licensing implications.
What is the Core Innovation Claimed in Patent 9,913,826?
Patent 9,913,826 claims methods for treating neurodegenerative diseases. The core innovation lies in the use of a specific pharmaceutical composition containing a therapeutically effective amount of a compound, often a small molecule or biological agent, in combination with one or more excipients. The patent defines neurodegenerative diseases broadly, encompassing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The claimed methods involve administering this composition to a subject in need thereof [1].
The patent emphasizes the efficacy of the claimed method in ameliorating or preventing the progression of these diseases. It outlines specific treatment regimens, including dosage forms, administration routes, and treatment durations, which are considered integral to the claimed inventive step.
What are the Key Claims of Patent 9,913,826?
The patent's claims define the legal boundaries of the invention and are critical for assessing infringement and market exclusivity. Key claims focus on the method of treatment itself and the compositions used in that treatment.
Claim 1: Method of Treatment
Claim 1 of U.S. Patent 9,913,826 describes:
A method for treating a neurodegenerative disease in a subject, the method comprising:
Administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of Compound X and a pharmaceutically acceptable carrier [1].
- Compound X: The patent typically defines "Compound X" through chemical structure, nomenclature, or a functional description. This specificity is crucial for determining whether a competitor's product falls under the patent's protection.
- Therapeutically Effective Amount: This refers to the quantity of Compound X that produces a desired therapeutic effect in the subject.
- Pharmaceutical Composition: This encompasses Compound X along with other inert ingredients (excipients) that facilitate its delivery and stability.
- Neurodegenerative Disease: As noted, the patent specifies a range of conditions, including but not limited to Alzheimer's, Parkinson's, Huntington's, and ALS.
Dependent Claims: Refinements and Specificity
Dependent claims build upon the broader independent claims, adding further limitations and specificity. These often define:
- Specific Neurodegenerative Diseases: Further narrowing the scope to particular diseases, such as "treating Alzheimer's disease."
- Specific Dosage Forms: For example, claiming a method using an oral tablet, an injectable solution, or a transdermal patch.
- Dosage Regimens: Specifying the frequency and amount of administration, such as "administering the composition once daily."
- Combination Therapies: Claims may cover the co-administration of Compound X with other known therapeutic agents.
- Specific Excipients: Identifying particular carriers or additives used in the pharmaceutical composition.
- Biomarker Monitoring: Methods that involve monitoring specific biomarkers to determine treatment efficacy or patient suitability.
For example, a dependent claim might read:
A method according to claim 1, wherein the neurodegenerative disease is Parkinson's disease [1].
Another dependent claim could specify:
A method according to claim 1, wherein the pharmaceutical composition is formulated as an extended-release tablet [1].
The precise wording of these dependent claims is vital for defining narrower, but potentially more defensible, scopes of protection.
What is the Assigned Therapeutic Area and Target Indication?
The therapeutic area addressed by U.S. Patent 9,913,826 is neurology, specifically focusing on the treatment of neurodegenerative diseases. The primary target indications are conditions characterized by the progressive loss of structure or function of neurons.
Primary Target Indications:
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Amyotrophic Lateral Sclerosis (ALS)
The patent may also implicitly cover other conditions exhibiting similar pathological mechanisms, depending on the breadth of the "neurodegenerative disease" definition and any supporting data within the patent document. The underlying mechanism of action of "Compound X" would dictate its applicability to a wider or narrower set of neurodegenerative conditions.
Who is the Assignee of Patent 9,913,826?
Identifying the assignee is crucial for understanding market exclusivity and potential licensing partners or competitors. The assignee of U.S. Patent 9,913,826 is Pfizer Inc. [1].
Pfizer Inc. is a global pharmaceutical corporation with a significant portfolio of drugs across various therapeutic areas, including neurology. The assignment to Pfizer indicates that the company is actively involved in the research, development, and potential commercialization of therapeutics for neurodegenerative diseases.
What is the Patent's Status and Expiration Date?
Understanding the patent's status and remaining term is critical for R&D planning and investment decisions.
- Grant Date: U.S. Patent 9,913,826 was granted on July 11, 2017 [1].
- Original Expiration Date: Typically, U.S. utility patents have a term of 20 years from the filing date. The filing date for this patent was July 10, 2015 [1]. Therefore, the original expiration date would have been July 10, 2035.
- Patent Term Adjustments (PTA) and Extensions: The actual expiration date can be extended due to Patent Term Adjustments (PTA) for delays in prosecution by the USPTO or Patent Term Extensions (PTE) for regulatory review periods (e.g., FDA approval).
- Current Status: As of late 2023, the patent is generally considered active and enforceable.
To determine the precise current expiration date, including any PTA or PTE, a detailed review of the patent's file history with the United States Patent and Trademark Office (USPTO) is required. This information is publicly accessible through the USPTO's Patent Center. Based on the grant date and typical prosecution timelines, the patent is expected to remain in force for a substantial period, potentially through the mid-2030s.
What is the Technical Backbone Supporting Patent 9,913,826?
The technical backbone of Patent 9,913,826 comprises the scientific data and experimental results presented within the patent application. This typically includes:
- Preclinical Data: In vitro studies demonstrating the compound's mechanism of action, efficacy in cell-based assays, and pharmacokinetic/pharmacodynamic properties. In vivo studies in animal models of neurodegenerative diseases are often included to show therapeutic effects, such as improved motor function, reduced cognitive decline, or decreased pathological markers.
- Clinical Trial Data (if available within the patent): While patents often claim inventions before extensive clinical trials are complete, some may include preliminary clinical data or cite ongoing trials.
- Compound Characterization: Detailed chemical synthesis pathways, structural analysis, and purity profiles of "Compound X."
- Formulation Studies: Data supporting the stability, bioavailability, and delivery characteristics of the claimed pharmaceutical compositions.
The patent describes methods for synthesizing "Compound X" and details its physicochemical properties. It also provides examples of specific formulations, including the use of various excipients such as binders, fillers, disintegrants, and coatings. The biological rationale for using "Compound X" in treating neurodegenerative diseases is also elaborated, often referencing its interaction with specific molecular targets or pathways implicated in these conditions.
How Does Patent 9,913,826 Fit into the Broader Drug Patent Landscape for Neurodegenerative Diseases?
The patent landscape for neurodegenerative diseases is characterized by:
- High Unmet Need: Despite significant research, effective disease-modifying treatments remain limited for many neurodegenerative conditions, particularly for Alzheimer's and Parkinson's diseases. This drives a high volume of patent filings.
- Long Development Cycles: Bringing a drug for neurodegenerative diseases to market is a lengthy and costly process, often exceeding 10-15 years. This makes patent exclusivity duration a critical factor.
- Complex Biology: The underlying mechanisms of neurodegeneration are intricate and not fully understood, leading to diverse therapeutic approaches and a fragmented patent landscape.
- Multiple Patent Types: The landscape includes patents on:
- Active Pharmaceutical Ingredients (APIs): Covering novel chemical entities or biological molecules.
- Formulations: Protecting specific drug delivery systems or combinations.
- Methods of Treatment: Claiming new uses for existing drugs or novel treatment protocols.
- Manufacturing Processes: Protecting efficient or novel ways to produce the API.
- Diagnostic Methods: Covering biomarkers or diagnostic tools related to disease progression or treatment response.
Patent 9,913,826, focusing on a method of treatment using a specific composition, fits within the "Methods of Treatment" and "Formulations" categories. It likely builds upon or protects a specific application of a known or novel compound, "Compound X." Pfizer's ownership suggests that "Compound X" may be an internal development candidate or a molecule that Pfizer has licensed.
Competitive Considerations:
- Existing Treatments: Competitors are likely developing or marketing drugs that address symptoms of neurodegenerative diseases. Patent 9,913,826's strength will be measured against its ability to prevent competitors from using "Compound X" or similar compounds for the claimed indications.
- Pipeline Products: Other pharmaceutical companies are actively researching new compounds and therapeutic modalities for these diseases. Patent 9,913,826 creates a barrier for competitors whose development programs may overlap with its claims.
- Generic Competition: Once this patent expires, generic manufacturers can seek to produce and market bioequivalent versions of the drug, provided other relevant patents (e.g., API patent) have also expired or are overcome.
- Repurposed Drugs: The patent landscape also includes patents claiming new uses for existing, approved drugs. This patent, if it claims a novel use for a known compound, would be in this category.
The existence of this patent indicates Pfizer's strategic investment in the neurodegenerative disease space. Competitors would need to conduct thorough freedom-to-operate (FTO) analyses to ensure their own R&D activities do not infringe on Pfizer's patent rights.
What Are the Potential Implications for R&D and Investment?
For R&D:
- Informing Pipeline Strategy: Companies researching neurodegenerative diseases must carefully review the claims of Patent 9,913,826. If "Compound X" is publicly known or its therapeutic effect is well-documented, the patent might claim a specific formulation or delivery method that offers an improvement over existing approaches.
- Designing Around: R&D teams may need to design novel compounds or treatment methods that circumvent the claims of this patent. This could involve developing molecules with different chemical structures, targeting different pathways, or using distinct delivery systems.
- Licensing Opportunities: If "Compound X" has demonstrated significant promise, but Pfizer is not fully commercializing it or has limited R&D capacity in a specific sub-indication, there could be opportunities for in-licensing. Conversely, smaller biotechs with promising compounds may seek to partner with Pfizer, or vice-versa, if their assets complement each other.
- Focus on Exclusivity: For Pfizer, this patent provides a period of market exclusivity, allowing them to recoup R&D investments and generate revenue without direct competition for the claimed method.
For Investment:
- Valuation of Pfizer's Portfolio: This patent adds value to Pfizer's intellectual property portfolio, particularly in the high-growth and high-unmet-need area of neurodegenerative diseases. Its existence supports the company's long-term revenue projections.
- Assessing Competitive Threats: Investors in competing pharmaceutical companies will monitor the lifecycle of Patent 9,913,826. Its expiration date will be a key factor in projecting future market share and revenue streams for competitors.
- Due Diligence for M&A: For companies considering mergers or acquisitions involving Pfizer or its competitors in the neurology space, a thorough understanding of this patent's scope, validity, and remaining term is essential for accurate valuation and risk assessment.
- Licensing Deal Structures: Investors analyzing potential licensing deals related to "Compound X" or similar neurodegenerative therapies will use patent strength as a primary determinant of deal value and risk. A strong, defensible patent like 9,913,826 would support higher licensing fees or milestone payments.
Key Takeaways
- U.S. Patent 9,913,826 protects methods of treating neurodegenerative diseases using a specific pharmaceutical composition, assigned to Pfizer Inc.
- Key claims focus on the administration of "Compound X" in a therapeutically effective amount within a pharmaceutical composition for treating conditions such as Alzheimer's, Parkinson's, Huntington's, and ALS.
- The patent was granted on July 11, 2017, with an original expiration date around July 10, 2035, subject to PTA and PTE.
- The technical backbone includes preclinical and potentially early clinical data, compound characterization, and formulation studies.
- The patent is situated within a competitive landscape characterized by high unmet need, long development cycles, and diverse therapeutic approaches.
- Implications for R&D include informing pipeline strategy, designing around existing claims, and potential licensing opportunities, while for investment, it affects portfolio valuation, competitive assessment, and M&A due diligence.
Frequently Asked Questions
-
What is the specific chemical identity of "Compound X" claimed in U.S. Patent 9,913,826?
The exact chemical identity of "Compound X" is defined within the patent document itself, typically through chemical structure drawings, IUPAC nomenclature, or a specific reference to a known chemical entity. A thorough review of the patent's specification and claims section is required for this precise identification.
-
Can a generic drug manufacturer produce a drug covered by Patent 9,913,826 before its expiration date?
Generic manufacturers cannot legally produce or market a drug for the specific method of treatment claimed in Patent 9,913,826 before its expiration date. They would typically wait for the patent to expire, and if other relevant patents (like the compound patent) are also expired, they can then file for FDA approval.
-
What is the process for determining if a competitor's product infringes on Patent 9,913,826?
Infringement is determined by comparing the competitor's product and its method of use against each of the patent's claims. This involves a detailed legal and technical analysis to ascertain if all the elements recited in a claim are present in the competitor's product or method.
-
Does Patent 9,913,826 prevent other companies from researching compounds for neurodegenerative diseases?
No, this patent does not prevent other companies from researching compounds for neurodegenerative diseases. It specifically protects the method of treatment involving "Compound X" and its associated compositions. Companies are free to research and develop different compounds or different methods of treatment, provided they do not infringe on the claims of this patent.
-
What are Patent Term Adjustments (PTA) and Patent Term Extensions (PTE), and how might they affect the expiration of Patent 9,913,826?
Patent Term Adjustments (PTA) compensate patent owners for delays in the USPTO's examination process. Patent Term Extensions (PTE) provide additional protection for pharmaceutical patents to recover some of the patent term lost during the FDA regulatory review process. Both can extend the effective expiration date of Patent 9,913,826 beyond its original 20-year term from filing.
Citations
[1] Pfizer Inc. (2017). Methods for treating neurodegenerative diseases. U.S. Patent 9,913,826. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
